2008
Management of Cardiovascular Disease in Renal Transplant Recipients
Shirali AC, Bia MJ. Management of Cardiovascular Disease in Renal Transplant Recipients. Clinical Journal Of The American Society Of Nephrology 2008, 3: 491-504. PMID: 18287250, PMCID: PMC6631091, DOI: 10.2215/cjn.05081107.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsRenal transplant recipientsTransplant recipientsRisk factorsCardiovascular diseaseKidney Disease Outcomes Quality InitiativeCardiovascular risk factorsHigher cardiovascular mortalityMajor risk factorBest available studiesCause of deathHealth care professionalsAllograft survivalGraft lossCardiovascular eventsLifestyle modificationCardiovascular mortalityImmunosuppressive agentsDrug therapyClinical acumenGeneral populationCare professionalsMajor causeDiseaseRecipientsAvailable studies
2006
A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period
Formica RN, Friedman AL, Lorber MI, Smith JD, Eisen T, Bia MJ. A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period. Nephrology Dialysis Transplantation 2006, 21: 1389-1394. PMID: 16431893, DOI: 10.1093/ndt/gfk058.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAmlodipineBlood Pressure DeterminationChi-Square DistributionDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHumansHypertensionKidney Failure, ChronicKidney TransplantationLosartanMaleMiddle AgedProbabilityRisk AssessmentSeverity of Illness IndexTreatment OutcomeConceptsRenal transplant recipientsPost-transplant periodEarly post-transplant periodARB useUse of ARBInitial therapyCCB groupImmediate post-transplant periodPost-transplant erythrocytosisPost-transplant hypertensionRisk of hyperkalaemiaPost-transplant managementSerum creatinine levelsChronic kidney diseaseII receptor blockersCalcium channel blockersNumber of patientsAldosterone systemARB groupKidney transplantationRenal transplantationTransplant recipientsCreatinine levelsRenal functionBlood pressure
2004
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers used for the treatment of hypertension appear to be safe in the early posttransplant period
Formica RN, Friedman AL, Lorber MI, Bia MJ. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers used for the treatment of hypertension appear to be safe in the early posttransplant period. Transplantation Proceedings 2004, 36: 2675-2678. PMID: 15621121, DOI: 10.1016/j.transproceed.2004.10.013.Peer-Reviewed Original ResearchConceptsAngiotensin II receptor blockersEarly posttransplant periodII receptor blockersCalcium channel blockersTreatment of hypertensionPosttransplant periodReceptor blockersEnzyme inhibitorsAcute renal dysfunctionAdministration of ACEAdult renal transplantsAppropriate clinical criteriaRenal transplant patientsGlomerular filtration rateType of transplantUse of ACESerum potassium concentrationAllograft functionPancreas transplantsRenal dysfunctionRenal transplantTransplant patientsSerum creatininePosttransplant erythrocytosisSerum potassium